Objective  Benign prostatic hyperplasia (BPH) is a common reproductive organ disease in elderly men. Early adoption of appropriate treatment methods in clinical practice is crucial for the treatment of benign prostatic hyperplasia. This study aimed to compare the therapeutic effects of tamsulosin and alfuzosin on benign prostatic hyperplasia and provide references for clinical rational drug use.

Method  A retrospective analysis was conducted on patients with benign prostatic hyperplasia admitted to Yongkang Hospital of Traditional Chinese Medicine from January 2020 to December 2020. The patients in the tamsulosin group received oral tamsulosin hydrochloride sustained-release capsules, while the patients in the alfuzosin group received alfuzosin hydrochloride sustained-release tablets. The international prostate symptom score (IPSS), international erectile function index (IIEF), maximum urinary flow (MFR), bladder residual urine volume (RU), prostate volume (PV), quality of life (SF-36 scale), and treatment effectiveness before and after treatment were compared to evaluate clinical efficacy. Liver function [alanine transferase (ALT), aspartate transferase (AST), total bilirubin], renal function [blood urea nitrogen (BUN) and creatinine (Cr)], prostate tumor markers serum free prostate specific antigen (F-PSA), and serum total prostate specific antigen (T-PSA) before and after treatment were compared to evaluate the safety.

Result  106 patients with benign prostatic hyperplasia were included (55 cases in tamsulosin group and 51 cases in alfuzosin group). Compared to before treatment, IPSS, RU and PV of the patients in the two groups after 6 months, 12 months, and 24 months of treatment were significantly decreased (P<0.05), and the quality of life were significantly increased (P<0.05). Compared with alfuzosin group, patients in tamsulosin group showed a significant decrease in IPSS, Ru and PV after 6 months, 12 months, and 24 months of treatment (P<0.05) and an increase in IIEF, MFR and quality of life (P<0.05). The total effective rate of the Tamsulosin group was significantly higher than that of the alfuzosin group (92.73% vs. 78.43%, P=0.035). There were no significant changes in liver and kidney function and prostate biomarker in both groups before and after treatment (P>0.05), and they were all in the normal range.

Conclusion  Both of tamsulosin and alfazosin could effectively improve the symptoms of benign prostatic hyperplasia and the quality of life of patients, with good safety. Furthermore, tamsulosin has a more significant therapeutic effect on patients with benign prostatic hyperplasia.

1.Ng M, Baradhi KM. Benign prostatic hyperplasia[M]. Treasure Island (FL): StatPearls Publishing, 2023.

2.Yu ZJ, Yan HL, Xu FH, et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia[J]. Front Pharmacol, 2020, 11:658. DOI: 10.3389/fphar.2020.00658.

3.GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019 [J]. Lancet Healthy Longev, 2022, 3(11): e754-e776. DOI: 10.1016/S2666-7568(22)00213-6.

4.Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia - what do we know?[J]. BJU Int, 2021, 127(4): 389-399. DOI: 10.1111/bju.15229.

5.Plochocki A, King B. Medical Treatment of Benign Prostatic Hyperplasia[J]. Urol Clin North Am, 2022, 49(2): 231-238. DOI:  10.1016/j.ucl.2021.12.003.

6.王晓明,蒲春晓,韩平.良性前列腺增生的药物治疗新进展[J].现代泌尿外科杂志, 2015, 20(6): 439-444.[Wang XM, Pu CX, Han P. New progress in drug treatment of benign prostatic hyperplasia[J]. Journal of Modern Urology, 2015, 20(6): 439-444.] DOI: 10.3969/j.issn.1009-8291.2015.06.022.

7.黄健.中国泌尿外科和男科疾病诊断治疗指南:2019版[M]. 北京: 科学出版社, 2020.

8.Yu SH, Jung SI. The potential role of urinary microbiome in benign prostate hyperplasia/lower urinary tract symptoms[J]. Diagnostics, 2022, 12(8): 1862. DOI: 10.3390/diagnostics12081862.

9.郝梦, 米尔扎提·麦麦提, 马璇, 等. 基于网络药理学和分子对接探讨西帕依麦孜彼子口服液抗良性前列腺增生的作用机制 [J]. 中国药师, 2021, 24(12): 2148-2166. [Hao M, Mierzhati MT, Ma X, et al. Mechanism of xipayimaizibizi oral liquid for anti-prostatic hyperplasia based on network pharmacologyand molecular docking[J]. China Pharmacist, 2021, 24(12): 2148-2166.] DOI: 10.19962/j.cnki.issn1008-049X.2021.12.002.

10.Mari A, Antonelli A, Cindolo L, et al. Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis[J]. Ther Adv Urol, 2021, 13: 1756287221993283. DOI: 10.1177/1756287221993283.

11.阎思宇, 黄兴, 陈征, 等. 良性前列腺增生经尿道前列腺等离子电切术临床路径释义[J]. 医学新知, 2022, 32(3): 214-222. [Yan SY, Huang X, Chen Z, et al. Clinical pathway interpretation of transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia[J]. New Medicine, 2022, 32(3): 214-222. DOI: 10.12173/j.issn.1004-5511.202205003.]                              

12.Jindan L, Xiao W, Liping X. Evolving role of silodosin for the treatment of urological disorders - a narrative review[J]. Drug Des Devel Ther, 2022, 16: 2861-2884. DOI: 10.2147/DDDT.S373659.

13.Laxman Prabhu GG, Prajapati H, Chaturvedi A, et al. Tamsulosin in urology: beyond benign prostatic hyperplasia[J]. Drugs Ther Perspect, 2019, 35: 181-184. DOI: 10.1007/s40267-019-00611-1.

14.IC VR, Kumar S, Bhuvaneswari S. A prospective study to evaluate the efficacy and adverse effects of alpha-blockers in the management of benign prostatic hyperplasia[J]. Natl J Physiol Pharm Pharmacol, 2023, 13(1): 163-163. DOI: 10.5455/njppp.2023.13.10495202228112022.

15.Yeung HEL, Sena SJ, Calopedos RJ, et al. Alfuzosin and its effect on ejaculatory dysfunction: a systematic review[J]. World J Mens Health, 2021, 39(2): 186-194. DOI: 10.5534/wjmh.180024.

16.Martin DJ, Lluel P, Guillot E, et al. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists[J]. J Pharmacol Exp Ther, 1997, 282(1): 228-235. https://pubmed.ncbi.nlm.nih.gov/9223558/.

17.Sasaki S, Tomiyama Y, Kobayashi S, et al. Characterization of α1-adrenoceptor subtypes mediating contraction in human isolated ureters [J]. Urology, 2011, 77(3): 762.e13-7. DOI: 10.1016/j.urology.2010.09.034.

18.Lapitan MC, Acepcion V, Mangubat J. A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial[J]. J Int Med Res, 2005, 33(5): 562-573. DOI: 10.1177/147323000503300512.

19.Griwan MS, Santosh KS, Indora J. Comparison of alfuzosin and tamsulosin once daily for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized, prospective study[J]. Urotoday International Journal, 2010, 3. DOI: 10.3834/uij.1944-5784.2010.06.14t2.

20.Matsukawa Y, Takai S, Majima T, et al. Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics[J]. Ther Adv Urol, 2018, 10, 263-272. DOI: 10.1177/1756287218783646.

21.Joo KJ, Sung WS, Park SH, et al. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia[J]. J Int Med Res, 2012, 40: 899-908. DOI: 10.1177/147323001204000308.